Can I Take Resveratrol with Zetia (Ezetimibe)?

What Is Ezetimibe and How Does It Work?

Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine. At its standard dose of 10 mg daily, ezetimibe reduces LDL-cholesterol by approximately 18 to 20% as monotherapy, and by an additional 21 to 27% when added on top of a statin. The SHARP trial (N=9,270) demonstrated that ezetimibe combined with simvastatin 20 mg reduced major atherosclerotic events by 17% (RR 0.83, 95% CI 0.74 to 0.94) compared to placebo over 4.9 years. [1]

Ezetimibe Metabolism: The UGT1A3 Pathway

After oral absorption, ezetimibe undergoes phase II glucuronidation primarily via UGT1A3 and UGT2B15 in the small intestine and liver, producing ezetimibe-glucuronide, the pharmacologically active form that circulates through enterohepatic recirculation. [2] This metabolic step is the most clinically relevant point of contact between ezetimibe and resveratrol.

Ezetimibe does not rely on CYP3A4 for its primary metabolism to any meaningful degree. That means CYP3A4 inhibitors carry less concern than they would for, say, atorvastatin. The UGT pathway is the vulnerability here.

Bioavailability and Half-Life

Oral ezetimibe reaches peak plasma concentration within 4 to 12 hours, and its effective half-life is roughly 22 hours when the active glucuronide form is included. This long half-life justifies once-daily dosing and also means that any UGT inhibition persists throughout the full dosing interval.

What Is Resveratrol and Why Do People Take It?

Resveratrol is a polyphenolic stilbene found in grape skins, red wine, Japanese knotweed (Polygonum cuspidatum), and peanuts. Supplement doses in clinical trials have ranged from 75 mg to 5,000 mg per day, depending on the endpoint studied. The rationale for use spans cardiovascular protection, anti-aging via SIRT1 activation, blood glucose regulation, and anti-inflammatory effects.

Resveratrol's Lipid Effects

A 2017 meta-analysis of 21 RCTs (N=1,477) published in Nutrition, Metabolism and Cardiovascular Diseases found that resveratrol supplementation did not significantly lower LDL-C compared to placebo (mean difference: -0.04 mmol/L, P=0.71), but did modestly reduce total cholesterol in subgroups using doses above 500 mg/day. [3] A separate 2021 review in the European Journal of Nutrition reported that resveratrol at 100 to 500 mg daily reduced triglycerides by roughly 8 to 12 mg/dL in insulin-resistant adults. [4]

Resveratrol's additive LDL-C lowering effect on top of ezetimibe is therefore likely modest to negligible, not the kind of pharmacodynamic amplification that would drive hypocholesterolemia to dangerous levels.

Resveratrol's Estrogenic Activity

Resveratrol acts as a selective estrogen receptor modulator (SERM), binding both ER-alpha and ER-beta with affinities roughly 7,000-fold lower than estradiol. [5] For most patients on ezetimibe alone, this carries no direct drug interaction. Patients combining resveratrol with estradiol-based HRT, tamoxifen, or raloxifene should discuss the combination with their prescriber given the theoretical additive or antagonistic ER effects.

The Core Interaction: Resveratrol, UGT Enzymes, and Ezetimibe

This is the section where the pharmacology becomes concrete.

UGT Inhibition by Resveratrol: What the Data Show

In-vitro studies have consistently shown that resveratrol inhibits UGT1A1, UGT1A3, UGT1A6, and UGT1A9. A 2015 study published in Drug Metabolism and Pharmacokinetics tested resveratrol's inhibitory constants (Ki) against multiple UGT isoforms and found Ki values for UGT1A1 of approximately 2.3 µM, suggesting meaningful inhibition at pharmacologically achievable tissue concentrations. [6] Since ezetimibe glucuronidation depends on UGT1A3, this raises a plausible, if unconfirmed, interaction.

The practical consequence of UGT1A3 inhibition would be reduced conversion of ezetimibe to its active glucuronide form. This could theoretically reduce ezetimibe's efficacy rather than increase its toxicity. The direction of concern is reduced drug effect, not toxicity.

CYP3A4 Inhibition: Less Relevant Here

Resveratrol inhibits CYP3A4 with an IC50 of approximately 12 to 15 µM in in-vitro systems, a range approached at high supplemental doses (above 500 mg/day orally). [7] For ezetimibe, this matters less than the UGT concern because ezetimibe's primary clearance path does not run through CYP3A4. For patients taking ezetimibe combined with a CYP3A4-sensitive statin (simvastatin, lovastatin, or atorvastatin), resveratrol-driven CYP3A4 inhibition could modestly raise statin plasma levels and warrant closer monitoring for myopathy.

CYP2C9 and Resveratrol

Resveratrol also inhibits CYP2C9 at concentrations above 10 µM. [7] Ezetimibe does not rely on CYP2C9, so this isoform is not a direct concern for the ezetimibe-resveratrol pair. Patients combining resveratrol with warfarin (a CYP2C9 substrate) face a more pressing interaction concern than those on ezetimibe alone.

HealthRX Clinical Decision Framework: Resveratrol + Ezetimibe Risk Stratification

| Patient Profile | Interaction Risk | Action | |---|---|---| | Ezetimibe 10 mg monotherapy, resveratrol <500 mg/day | Low | No change needed; recheck LDL-C at next scheduled visit | | Ezetimibe + statin, resveratrol <500 mg/day | Low-moderate | Watch for statin myopathy symptoms; standard LFT monitoring | | Ezetimibe + statin, resveratrol >500 mg/day | Moderate | Discuss with prescriber; consider CK check if using CYP3A4-sensitive statin | | Ezetimibe + HRT or tamoxifen, any resveratrol dose | Moderate (ER concern) | Inform prescribing physician; monitor hormone-sensitive endpoints | | Ezetimibe monotherapy, resveratrol >1,000 mg/day | Low-moderate | Monitor LDL-C at 6 weeks; theoretical risk of reduced ezetimibe efficacy |

What Human Studies Actually Exist?

No published RCT has directly studied the pharmacokinetic interaction between resveratrol and ezetimibe in humans as of January 2025. This is not unusual: combination studies between branded pharmaceuticals and dietary supplements are rarely funded because neither category can be exclusively patented against the other.

The available evidence pyramid for this combination is:

1. In-vitro enzyme inhibition data (Ki / IC50 values for UGT and CYP isoforms).
2. Pharmacokinetic modeling extrapolating from in-vitro to predicted in-vivo exposure.
3. Single-drug human PK studies that describe ezetimibe's UGT dependence and resveratrol's plasma concentrations after oral dosing.
4. Case reports: none identified in the FDA Adverse Event Reporting System (FAERS) as of the most recent publicly available quarterly data.

The absence of case reports in FAERS is meaningful but not reassuring on its own. FAERS is limited by substantial under-reporting of supplement-related interactions.

What In-Vitro to In-Vivo Extrapolation Suggests

Human oral bioavailability of resveratrol is low (roughly 1% of unchanged compound for most formulations) due to extensive first-pass metabolism and rapid glucuronidation and sulfation. [8] A 500 mg oral dose produces free resveratrol plasma concentrations in the range of 0.1 to 2 µM, below the Ki values established for UGT inhibition in most in-vitro studies. Micronized or liposomal resveratrol formulations increase bioavailability modestly but are unlikely to shift free plasma concentrations into the high-inhibition range.

This pharmacokinetic reality is the primary reason clinicians classify the ezetimibe-resveratrol interaction as low to low-moderate risk rather than clinically significant.

Does Resveratrol Affect Cholesterol Independently?

The question matters because patients and clinicians need to know whether adding resveratrol could amplify LDL-C lowering to a degree that would require ezetimibe dose adjustment.

The Evidence on Resveratrol and LDL-C

The 2017 Cochrane-adjacent meta-analysis (21 RCTs, N=1,477) cited earlier showed no statistically significant reduction in LDL-C. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease does not list resveratrol as a recommended adjunct lipid-lowering therapy. [9] Resveratrol is not included in the 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction. [10]

Clinically, the LDL-C pharmacodynamic interaction between resveratrol and ezetimibe is probably negligible. Patients should not expect to lower their ezetimibe dose or substitute resveratrol for ezetimibe.

SIRT1 and Cholesterol Metabolism

Resveratrol activates SIRT1, a deacetylase that regulates hepatic cholesterol synthesis and bile acid pathways. Animal studies have shown SIRT1 activation can reduce hepatic cholesterol output, but these effects do not translate cleanly to human LDL-C endpoints at typical supplement doses. [11]

Practical Guidance: Timing, Dosing, and Monitoring

Dose Separation

Ezetimibe's long half-life (22 hours, including the active glucuronide) means that a separation window of a few hours provides no meaningful pharmacokinetic protection against UGT inhibition. Unlike drug interactions mediated by transient peak enzyme inhibition, UGT inhibition by resveratrol would be relatively persistent throughout the day at higher supplement doses. Dose separation is not an effective mitigation strategy for this particular pair.

Optimal Resveratrol Dose Range

Patients who want to continue resveratrol while on ezetimibe are best served by staying at or below 500 mg/day of standard (non-enhanced-bioavailability) resveratrol. At this dose, free plasma concentrations remain below the threshold for meaningful UGT1A3 inhibition based on current in-vitro Ki data. Doses above 1,000 mg/day increase this risk modestly and provide no additional documented cardiovascular benefit in human trials.

LDL-C Monitoring Schedule

The standard approach: recheck a fasting lipid panel 6 to 12 weeks after any medication or supplement change. If LDL-C rises after adding resveratrol while maintaining the same ezetimibe dose, the most plausible explanation is reduced ezetimibe efficacy via UGT inhibition. In that scenario, stopping or reducing resveratrol is the first intervention to consider before adjusting the ezetimibe dose.

When to Involve Your Prescriber Immediately

• LDL-C rises more than 15% from baseline after adding resveratrol.
• You also take warfarin, a CYP2C9-sensitive drug, or a CYP3A4-sensitive statin alongside ezetimibe.
• You are on tamoxifen, aromatase inhibitors, or estradiol-based HRT and want to add resveratrol above 500 mg/day.
• You develop unexplained muscle aches, weakness, or dark urine (relevant if a statin is also part of your regimen).

Resveratrol Formulations and Bioavailability: Why the Label Dose Is Not the Tissue Dose

Standard resveratrol capsules deliver trans-resveratrol, the biologically active isomer. Oral bioavailability of trans-resveratrol is approximately 1% for free (unconjugated) compound because of rapid phase II metabolism in the gut wall and liver. [8]

Enhanced-Bioavailability Formulations

Micronized resveratrol, phospholipid complexes (e.g., Longevinex, Meriva-style matrices), and liposomal formulations report 3 to 8-fold increases in Cmax compared to standard capsules. A 2014 study in Cancer Prevention Research testing a micronized resveratrol formulation (SRT501) at 5,000 mg/day found peak plasma concentrations of approximately 4 µM. [12] This range approaches Ki values for UGT inhibition and argues for greater caution with high-dose enhanced formulations.

If your patient is using a commercial longevity product or sports supplement containing "enhanced" resveratrol at doses above 500 mg, treat the interaction risk one category higher than the standard-capsule risk table above.

Special Populations

Patients With Hepatic Impairment

Both ezetimibe and resveratrol undergo significant hepatic metabolism. Mild hepatic impairment does not require ezetimibe dose adjustment, but moderate to severe hepatic impairment is a labeled contraindication for ezetimibe monotherapy and combination products. [13] Resveratrol at high doses has shown hepatotoxic signals in animal studies; human data are sparse but the FDA has received case reports of hepatotoxicity associated with resveratrol-containing supplements. Avoid high-dose resveratrol in any patient with hepatic disease.

Patients With Diabetes or Insulin Resistance

Resveratrol may modestly improve insulin sensitivity via SIRT1 and AMPK activation. The CALERIE-adjacent trials and smaller RCTs have shown reductions in fasting glucose of 5 to 7 mg/dL at doses of 500 to 1,000 mg/day. [4] This is not a contraindication with ezetimibe, but diabetic patients combining resveratrol with metformin or insulin should monitor blood glucose during the first 4 to 8 weeks.

Post-Menopausal Patients on HRT

This group warrants specific attention. Resveratrol's SERM-like activity at ER-alpha and ER-beta may add to, or partially antagonize, the effects of oral or transdermal estradiol. No large trial has evaluated this combination in a cardiovascular lipid context. Clinicians should note that the Endocrine Society's 2022 Clinical Practice Guideline on menopause recommends discussing all supplements with hormonal activity with the patient's prescribing clinician before initiation. [14]

What the FDA and Major Guidelines Say About Supplement-Drug Interactions

The FDA does not classify resveratrol as a drug, so no formal drug interaction labeling exists for the ezetimibe-resveratrol pair. The Zetia (ezetimibe) prescribing information lists bile acid sequestrants (cholestyramine, colesevelam), cyclosporine, and fibrates as the primary interaction concerns; it does not mention resveratrol specifically. [13]

The 2022 ACC/AHA guideline on lipid management acknowledges that dietary supplements marketed for cholesterol lowering have limited evidence and that clinicians should ask about supplement use at every lipid management visit. The guideline states: "Clinicians should counsel patients that the efficacy and safety of most dietary supplements for LDL-C lowering have not been established in adequately powered randomized trials." [10]

The Office of Dietary Supplements (NIH) maintains a Dietary Supplement Label Database that lists no specific interaction between resveratrol and ezetimibe, though it flags resveratrol's CYP and UGT inhibitory profile as an area requiring clinical judgment. [15]

Key Takeaways for Clinicians and Patients

Resveratrol at doses below 500 mg/day from standard (non-enhanced-bioavailability) formulations carries a low risk of clinically meaningful pharmacokinetic interaction with ezetimibe 10 mg daily, based on current in-vitro data and the known low oral bioavailability of free resveratrol. The theoretical mechanism runs through UGT1A3 inhibition reducing ezetimibe glucuronidation and potentially blunting ezetimibe efficacy, not through increased toxicity.

Higher doses (above 500 mg/day) or enhanced-bioavailability formulations narrow the gap between achieved plasma concentrations and in-vitro inhibitory thresholds, and should prompt a conversation with the prescribing clinician and a lipid recheck at 6 weeks.

For patients who are also on a CYP3A4-sensitive statin (simvastatin or lovastatin), CYP2C9-metabolized anticoagulants, or ER-active hormonal therapies, resveratrol carries additional interaction concerns that exist independently of the ezetimibe pathway.

Check a fasting lipid panel 6 weeks after adding or changing resveratrol dose while on ezetimibe.